Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Inventory (2018 - 2025)

10x Genomics (TXG) has disclosed Inventory for 8 consecutive years, with $56.3 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 32.21% to $56.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.3 million through Dec 2025, down 32.21% year-over-year, with the annual reading at $56.3 million for FY2025, 32.21% down from the prior year.
  • Inventory hit $56.3 million in Q4 2025 for 10x Genomics, down from $62.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $94.0 million in Q3 2024 to a low of $38.5 million in Q1 2021.
  • Historically, Inventory has averaged $71.0 million across 5 years, with a median of $74.2 million in 2023.
  • Biggest five-year swings in Inventory: skyrocketed 103.6% in 2021 and later plummeted 34.12% in 2025.
  • Year by year, Inventory stood at $60.0 million in 2021, then surged by 36.13% to $81.6 million in 2022, then fell by 9.71% to $73.7 million in 2023, then rose by 12.75% to $83.1 million in 2024, then tumbled by 32.21% to $56.3 million in 2025.
  • Business Quant data shows Inventory for TXG at $56.3 million in Q4 2025, $62.0 million in Q3 2025, and $69.0 million in Q2 2025.